Curing hepatitis C with pills: a step toward global control
- 15 October 2010
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 376 (9751), 1441-1442
- https://doi.org/10.1016/s0140-6736(10)61497-3
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2010
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialThe Lancet, 2010
- Public health impact of antiviral therapy for hepatitis C in the United StatesHepatology, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Market uptake of new antiviral drugs for the treatment of hepatitis CJournal of Hepatology, 2008
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis CAnnals of Internal Medicine, 2002